193 related articles for article (PubMed ID: 8643355)
41. Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors.
Amendt BA; Si ZH; Stoltzfus CM
Mol Cell Biol; 1995 Aug; 15(8):4606-15. PubMed ID: 7623852
[TBL] [Abstract][Full Text] [Related]
42. Characterization of a nuclear retention sequence within the 3' region of the HIV-2 envelope gene.
Keller R; Montagnier L; Cordonnier A
Virology; 1993 Jan; 192(1):33-7. PubMed ID: 8517024
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
44. Tat and Rev: positive regulators of HIV gene expression.
Rosen CA; Pavlakis GN
AIDS; 1990 Jun; 4(6):499-509. PubMed ID: 2201316
[No Abstract] [Full Text] [Related]
45. Fragments of the HIV-Tat protein specifically bind TAR RNA.
Dis Markers; 1991; 9(1):58-9. PubMed ID: 1742953
[No Abstract] [Full Text] [Related]
46. Selection of RNA-binding peptides in vivo.
Harada K; Martin SS; Frankel AD
Nature; 1996 Mar; 380(6570):175-9. PubMed ID: 8600395
[TBL] [Abstract][Full Text] [Related]
47. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains.
Bilodeau PS; Domsic JK; Stoltzfus CM
J Virol; 1999 Dec; 73(12):9764-72. PubMed ID: 10559286
[TBL] [Abstract][Full Text] [Related]
48. A docking and modelling strategy for peptide-RNA complexes: applications to BIV Tat-TAR and HIV Rev-RBE.
Srinivasan J; Leclerc F; Xu W; Ellington AD; Cedergren R
Fold Des; 1996; 1(6):463-72. PubMed ID: 9080192
[TBL] [Abstract][Full Text] [Related]
49. Methylphosphonate mapping of phosphate contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins.
Pritchard CE; Grasby JA; Hamy F; Zacharek AM; Singh M; Karn J; Gait MJ
Nucleic Acids Res; 1994 Jul; 22(13):2592-600. PubMed ID: 8041622
[TBL] [Abstract][Full Text] [Related]
50. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.
Lee TC; Sullenger BA; Gallardo HF; Ungers GE; Gilboa E
New Biol; 1992 Jan; 4(1):66-74. PubMed ID: 1536832
[TBL] [Abstract][Full Text] [Related]
51. Splicing affects presentation of RNA dimerization signals in HIV-2 in vitro.
Lanchy JM; Szafran QN; Lodmell JS
Nucleic Acids Res; 2004; 32(15):4585-95. PubMed ID: 15333691
[TBL] [Abstract][Full Text] [Related]
52. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.
Smith C; Lee SW; Wong E; Gallardo H; Page K; Gaspar O; Lebkowski J; Gilboa E
Antiviral Res; 1996 Oct; 32(2):99-115. PubMed ID: 8891169
[TBL] [Abstract][Full Text] [Related]
53. A Janus splicing regulatory element modulates HIV-1 tat and rev mRNA production by coordination of hnRNP A1 cooperative binding.
Marchand V; Méreau A; Jacquenet S; Thomas D; Mougin A; Gattoni R; Stévenin J; Branlant C
J Mol Biol; 2002 Nov; 323(4):629-52. PubMed ID: 12419255
[TBL] [Abstract][Full Text] [Related]
54. A molecular rheostat. Co-operative rev binding to stem I of the rev-response element modulates human immunodeficiency virus type-1 late gene expression.
Mann DA; Mikaélian I; Zemmel RW; Green SM; Lowe AD; Kimura T; Singh M; Butler PJ; Gait MJ; Karn J
J Mol Biol; 1994 Aug; 241(2):193-207. PubMed ID: 8057359
[TBL] [Abstract][Full Text] [Related]
55. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators.
Hamasaki K; Ueno A
Bioorg Med Chem Lett; 2001 Feb; 11(4):591-4. PubMed ID: 11229778
[TBL] [Abstract][Full Text] [Related]
56. Tailoring the peptide-binding specificity of an RNA by combinations of specificity-altering mutations.
Sugaya M; Nishimura F; Katoh A; Harada K
Nucleosides Nucleotides Nucleic Acids; 2008 May; 27(5):534-45. PubMed ID: 18569791
[TBL] [Abstract][Full Text] [Related]
57. [Regulatory mechanism of HIV gene expression].
Hatanaka M
Nihon Rinsho; 1993 Sep; 51 Suppl():43-57. PubMed ID: 8271415
[No Abstract] [Full Text] [Related]
58. Binding of an HIV Rev peptide to Rev responsive element RNA induces formation of purine-purine base pairs.
Battiste JL; Tan R; Frankel AD; Williamson JR
Biochemistry; 1994 Mar; 33(10):2741-7. PubMed ID: 8130185
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
60. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription.
Bohjanen PR; Colvin RA; Puttaraju M; Been MD; Garcia-Blanco MA
Nucleic Acids Res; 1996 Oct; 24(19):3733-8. PubMed ID: 8871552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
